A PHASE 1/2 FEASIBILITY, SAFETY, AND ACTIVITY STUDY OF PSCA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR ENGINEERED T CELLS (BPX-601) IN SUBJECTS WITH PREVIOUSLY TREATED ADVANCED SOLID TUMORS

Contact:

NCT Number:

Protocol:

AAAR9974

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I/II

The purpose of this study is to test what dose of BPX-601 can be given safely with rimiducid to patients with certain types of cancer. The study will look for side effects (good and bad) and how your body responds to the treatment. The study will also see if the treatment helps to stop your cancer from growing or spreading. BPX-601 is a treatment made from your white blood cells (T cells). Your T cells are modified in a laboratory by adding a chimeric antigen receptor gene called a CAR. The CAR recognizes a tumor marker on your cancer. The addition of the CAR is thought to help your own T cells to find and attack your cancer.

Are you Eligible? (Inclusion Criteria)

  • Are you 18 years of age or older?
  • Do you have Metastatic pancreatic ductal adenocarcinoma, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, or hormone-refractory adenocarcinoma of the prostate?
  • Are you fully active or at least able to carry out work of a light or sedentary nature?

Specialty Area(s)

Pancreatic Cancer, Prostate Cancer, Stomach Cancer, Immunotherapy

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032